Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 18 May

Sophia Mavridis
May 18, 2022

Morning Bell 17 May

Sophia Mavridis
May 17, 2022

Morning Bell 16 May

Paulina Peters
May 16, 2022

Weekly Wrap 13 May

Sophia Mavridis
May 13, 2022

Morning Bell 12 May

Paulina Peters
May 12, 2022

Morning Bell 11 May

Sophia Mavridis
May 11, 2022

Morning Bell 10 May

Paulina Peters
May 10, 2022

Morning Bell 9 May

Sophia Mavridis
May 9, 2022

Weekly Wrap 6 May

Sophia Mavridis
May 6, 2022

Morning Bell 5 May

Paulina Peters
May 5, 2022

Morning Bell 4 May

Sophia Mavridis
May 4, 2022

Morning Bell 3 May

Paulina Peters
May 3, 2022